Published on 3 May 2023 on Benzinga via Yahoo Finance
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) reported Q1 revenues of $7.68 million, down from $9.3 million a year ago but slightly beating the $7.43 million consensus.
Operating expenses reached $29.2 million compared with $27.6 million a year ago, primarily driven by continued investment in R&D for EYP-1901 development, offset by a reduction in sales and marketing spend for DEXYCU.